Drug | AUC_{0-∞} (h · mg/liter) | ||||
---|---|---|---|---|---|

Observed value for cohort^{a}: | Predicted value for cohort^{b}: | Value for adult reference population^{c} (n = 16) | |||

1 (≥12 to <18 yr) | 2 (≥6 to <12 yr) | 3 (≥2 to <6 yr) | 4 (≥3 mo to <2 yr) | ||

Ceftazidime | 230.6 (30.7) | 221.2 (17.4) | 255.32 (43.95) | 286.27 (37.13) | 289.0^{d} (15.4) |

Avibactam | 36.4 (33.6) | 34.8 (22.6) | 43.25 (12.14) | 48.99 (10.64) | 42.1^{e} (16.0) |

↵a Data for cohorts 1 and 2 are geometric means (percent coefficients of variation).

↵b Data for cohorts 3 and 4 are means (SD) based on population pharmacokinetic model predictions (42).

↵c Values are geometric means (percent coefficients of variation) for observed exposures from a phase I study in healthy adult volunteers on day 1 after receiving a single dose of ceftazidime-avibactam (2,000 to 500 mg) (44).

↵d

*n*= 15.↵e

*n*= 13.